ATE437241T1 - Verfahren zum ermitteln der wirksamkeit eines anthracyclin-antikrebsmittels - Google Patents

Verfahren zum ermitteln der wirksamkeit eines anthracyclin-antikrebsmittels

Info

Publication number
ATE437241T1
ATE437241T1 AT07120168T AT07120168T ATE437241T1 AT E437241 T1 ATE437241 T1 AT E437241T1 AT 07120168 T AT07120168 T AT 07120168T AT 07120168 T AT07120168 T AT 07120168T AT E437241 T1 ATE437241 T1 AT E437241T1
Authority
AT
Austria
Prior art keywords
anticancer agent
determining
anthracycline anticancer
susceptibility
effectiveness
Prior art date
Application number
AT07120168T
Other languages
English (en)
Inventor
Amane Harada
Tomokazu Yoshida
Original Assignee
Sysmex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sysmex Corp filed Critical Sysmex Corp
Application granted granted Critical
Publication of ATE437241T1 publication Critical patent/ATE437241T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/44—Multiple drug resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT07120168T 2006-11-13 2007-11-07 Verfahren zum ermitteln der wirksamkeit eines anthracyclin-antikrebsmittels ATE437241T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2006307276A JP4795203B2 (ja) 2006-11-13 2006-11-13 アンスラサイクリン系抗癌剤の感受性判定方法及びそのシステム

Publications (1)

Publication Number Publication Date
ATE437241T1 true ATE437241T1 (de) 2009-08-15

Family

ID=38969820

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07120168T ATE437241T1 (de) 2006-11-13 2007-11-07 Verfahren zum ermitteln der wirksamkeit eines anthracyclin-antikrebsmittels

Country Status (5)

Country Link
US (1) US7718393B2 (de)
EP (1) EP1921170B1 (de)
JP (1) JP4795203B2 (de)
AT (1) ATE437241T1 (de)
DE (1) DE602007001656D1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12366585B2 (en) 2006-05-18 2025-07-22 Caris Mpi, Inc. Molecular profiling of tumors
IL313131A (en) * 2009-02-11 2024-07-01 Caris Mpi Inc Molecular characterization of tumors
EP2432872B1 (de) * 2009-05-22 2015-09-30 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Akt-phosphorylierung an ser473 als indikator für chemotherapie auf der basis von taxan
JP5830249B2 (ja) * 2010-03-31 2015-12-09 シスメックス株式会社 癌細胞のアンスラサイクリン系抗癌剤への感受性の判定方法及びコンピュータプログラム

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4317913B2 (ja) * 2000-04-14 2009-08-19 ベンタナ・メデイカル・システムズ・インコーポレーテツド Aktタンパク質発現の定量方法
AU2003291736A1 (en) * 2002-11-05 2004-06-03 Cell Signaling Technology, Inc. Methods and materials for examining pathways associated with glioblastoma progression
WO2004053497A2 (en) * 2002-12-11 2004-06-24 Ventana Medical Systems, Inc. Method for predicting the response to her2-directed therapy
EP1599573B1 (de) * 2003-02-17 2013-06-19 Cold Spring Harbor Laboratory Modell zur untersuchung der rolle von genen bei tumorresistenz in der chemotherapie
JP2004357552A (ja) * 2003-06-03 2004-12-24 Hitachi Ltd 作用物質による効果推定方法及びスクリーニング方法
EP2439284B1 (de) * 2004-03-31 2019-05-08 The General Hospital Corporation Verfahren zur Bestimmung des Ansprechens von Krebs auf den epidermalen Wachstumsfaktorrezeptor gerichtete Behandlungen
JPWO2006082866A1 (ja) * 2005-02-01 2008-06-26 萬有製薬株式会社 p53の機能異常の検出方法、癌の分子診断方法及び癌治療に有効な化合物の評価方法
AR053272A1 (es) * 2005-05-11 2007-04-25 Hoffmann La Roche Determinacion de responsivos a la quimioterapia

Also Published As

Publication number Publication date
EP1921170A3 (de) 2008-06-04
US20080124750A1 (en) 2008-05-29
EP1921170A2 (de) 2008-05-14
JP4795203B2 (ja) 2011-10-19
US7718393B2 (en) 2010-05-18
DE602007001656D1 (de) 2009-09-03
EP1921170B1 (de) 2009-07-22
JP2008122258A (ja) 2008-05-29

Similar Documents

Publication Publication Date Title
WO2008073899A3 (en) Prrg4-associated compositions and methods of use thereof in methods of tumor diagnosis
EP1849001A4 (de) Seitenstrom-testsatz und verfahren zum nachweis eines analyten
EP2186238A4 (de) Vorrichtung und verfahren zum durchführen von sicheren finanztransaktionen
EP2056715A4 (de) Funktionelle untersuchungs- und behandlungskatheter sowie verfahren zu ihrer verwendung in der lunge
WO2009085234A3 (en) Use of micro-rna as a biomarker of immunomodulatory drug activity
EP2203209A4 (de) Kathetergerät und verfahren zur behandlung von gefässen
EP2187829A4 (de) System und verfahren zur messung einer impedanz mittels eines katheters, z.b. eines ablationskatheters
EP2209495A4 (de) Taz/wwtr1 zur diagnose und behandlung von krebs
WO2010091049A3 (en) Diagnosis and treatment of cancer
WO2008095492A3 (en) A method for diagnosing atherosclerotic plaques by measurement of cd36
WO2013063155A3 (en) Companion diagnostic for anti-hyaluronan agent therapy and methods of use thereof
DE112007003573A5 (de) Verfahren zum Bestimmen eines eine Erdimpedanz angebenden Einstellwertes und Messeinrichtung
EP2118654A4 (de) Diagnostischer test zum nachweis eines moleküls oder arzneistoffs in vollblut
CY1115439T1 (el) Μεθοδοι και νουκλεϊκα οξεα για αναλυσεις διαταραχων του κυτταρικου πολλαπλασιασμου
EP4218570A3 (de) Polymermembranen für kontinuierliche analytsensoren
EP1983889A4 (de) Verfahren und vorrichtung zum testen von blutgerinnung
BR112012002594A2 (pt) dispositivo e método para detectar sangue ou constituintes de sangue no sistema de líquido de um dispositivo para tratamento de sangue extracorpóreo
DE112007000332A5 (de) Vorrichtung und Verfahren zum Bestimmen eines Freiraums vor einem Fahrzeug
EP4183338A4 (de) Vorrichtung zum nachweis von analyten in körperflüssigkeiten
EP2164990A4 (de) Zusammensetzungen, kits und verfahren zur identifizierung, beurteilung, vorbeugung und therapie von krebs
DE602007001656D1 (de) Verfahren zum Ermitteln der Wirksamkeit eines Anthracyclin-Antikrebsmittels
DE602006009890D1 (de) Verfahren zum Hinzufügen eines Effekts und Vorrichtung zum Hinzufügen eines Effekts
DE502007004852D1 (de) Vorrichtung mit fluidverteiler und messwerterfassung sowie verfahren zum betrieb eines mit rauchgas durchströmten kessels
WO2009022988A3 (en) Vhz for diagnosis and treatment of cancer
SG179070A1 (en) Method to identify a patient with an increased likelihood of responding to an anti-cancer agent

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties